Nitric oxide and adverse events of vascular endothelial growth factor inhibitors

References

• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71
   PubMed Web of Science ®Google Scholar
• Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95
   PubMed Web of Science ®Google Scholar
• Ku DD, Zaleski JK, Liu S, et al. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:H586-92
   PubMed Web of Science ®Google Scholar
• Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001;49:568-81
   PubMed Web of Science ®Google Scholar
• Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999;41:773-80
   PubMed Web of Science ®Google Scholar
• Wu MH, Yuan SY, Granger HJ. The protein kinase MEK1/2 mediates vascular endothelial growth factor- and histamine-induced hyperpermeability in porcine coronary venules. J Physiol 2005;563(Pt 1):95-104
   PubMed Web of Science ®Google Scholar
• Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I, et al. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007;7:127-34
   PubMed Web of Science ®Google Scholar
• Dirix LY, Maes H, Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol 2007;18:1121-2
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-30
   PubMed Web of Science ®Google Scholar
• Thachil J. Nitric oxide depletion is responsible for the adverse effects of vascular endothelial growth factor inhibitors. Nat Clin Pract Nephrol 2008;4:536-7
   PubMedGoogle Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28:2280-5
   PubMed Web of Science ®Google Scholar
• Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542
   PubMed Web of Science ®Google Scholar
• Freedman JE, Loscalzo J. Nitric oxide and its relationship to thrombotic disorders. J Thromb Haemost 2003;1:1183-8
   PubMed Web of Science ®Google Scholar
• Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46:439-48
   PubMed Web of Science ®Google Scholar
• Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76
   PubMed Web of Science ®Google Scholar
• Waddington S, Cook HT, Reaveley D, et al. L-arginine depletion inhibits glomerular NO synthesis and exacerbates rat nephrotoxic nephritis. Kidney Int 1996;49:1090-6
   PubMed Web of Science ®Google Scholar
• Heeringa P, Steenbergen E, van Goor H. A protective role for endothelial NO synthase in glomerulonephritis. Kidney Int 2002;61:822-5
   PubMed Web of Science ®Google Scholar
• Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 1992;90:1718-25
   PubMed Web of Science ®Google Scholar
• Soneja A, Drews M, Malinski T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep 2005;57(Suppl):108-19
   PubMedGoogle Scholar
• Schaffer MR, Tantry U, Gross SS, et al. Nitric oxide regulates wound healing. J Surg Res 1996;63:237-40
   PubMed Web of Science ®Google Scholar
• Witte MB, Kiyama T, Barbul A. Nitric oxide enhances experimental wound healing in diabetes. Br J Surg 2002;89:1594-601
   PubMed Web of Science ®Google Scholar
• Lee PC, Salyapongse AN, Bragdon GA, et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 1999;277:H1600-8
   PubMed Web of Science ®Google Scholar
• Walraven M, Witteveen PO, Lolkema MP, et al. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2011;14:135-41
   Google Scholar
• Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-42
   PubMed Web of Science ®Google Scholar
• Brzozowski T, Konturek PC, Konturek SJ, et al. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs. Dig Liver Dis 2000;32:583-94
   PubMedGoogle Scholar
• Brzozowski T, Konturek SJ, Sliwowski Z, et al. Role of arginine, a substrate for nitric oxide synthase in gastroprotection and ulcer healing. J Gastroenterol 1997;32:442-52
   PubMed Web of Science ®Google Scholar
• Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 2008;29:1043-9
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab 1996;16:981-7
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011;29:632-8
   PubMed Web of Science ®Google Scholar
• Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999;99:2113-17
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Darnell C, Rixe O. Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity. Cancer J 2010;16:635-42
   PubMed Web of Science ®Google Scholar